Carvedilol and Omnicef drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Carvedilol (carvedilol) and Omnicef (cefdinir). Common drug interactions include anxiety among females and coronary artery disease among males.

The phase IV clinical study analyzes what interactions people have when they take Carvedilol and Omnicef. It is created by eHealthMe based on reports of 50 people who take the same drugs from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,649 Carvedilol users. Check the latest studies of Carvedilol.

What is Omnicef?

Omnicef has active ingredients of cefdinir. It is often used in sinusitis. eHealthMe is studying from 2,774 Omnicef users. Check the latest studies of Omnicef.



On Jul, 13, 2026

50 people who take Carvedilol and Omnicef together, and have interactions are studied.

Carvedilol and Omnicef drug interactions.

What are the common drug interactions of Carvedilol and Omnicef, by gender? *:

female:

  1. Anxiety
  2. Depression
  3. Abdominal pain
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Candidiasis (candidiasis or thrush is a fungal infection)
  6. Constipation
  7. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  8. Haemoglobin decreased
  9. Pneumonia
  10. Sepsis (a severe blood infection that can lead to organ failure and death)

male:

  1. Coronary artery disease (plaque building up along the inner walls of the arteries of the heart, which narrows the arteries and restricts blood flow to the heart)
  2. Dyspnoea (difficult or laboured respiration)
  3. Bone disorder
  4. Cardiac disorder
  5. Cardiac failure congestive
  6. Cardiac valve disease (heart valve disease)
  7. Cyst (a closed sac)
  8. Dental caries
  9. Depression
  10. Dizziness

What are the common drug interactions of Carvedilol and Omnicef, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

  1. Chronic kidney disease
  2. Renal failure (kidney dysfunction)
  3. Nephrogenic anaemia (anaemia due to kidney disease)
  4. Renal tubular necrosis (death of kidney tubules)
  5. Death
  6. Hyperkalaemia (damage to or disease of the kidney)
  7. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  8. Nephropathy (damage to or disease of a kidney)
  9. Renal injury (kidney injury)
  10. Renal ischaemia (lack of blood supply to kidney)

40-49:

  1. Chronic kidney disease
  2. Hyperparathyroidism secondary (an abnormally high concentration of parathyroid hormone in the blood, resulting in weakening of the bones through loss of calcium-secondary)
  3. Nephrogenic anaemia (anaemia due to kidney disease)
  4. Renal failure (kidney dysfunction)
  5. Renal tubular necrosis (death of kidney tubules)

50-59:

  1. Sinus disorder (disease of sinus)
  2. Staphylococcal skin infection (skin infection by an infection with staphylococcus bacteria)
  3. Chronic kidney disease
  4. Renal failure (kidney dysfunction)
  5. Renal injury (kidney injury)
  6. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  7. Nephrogenic anaemia (anaemia due to kidney disease)
  8. Tubulointerstitial nephritis (a form of nephritis affecting the interstitium of the kidneys surrounding the tubules)
  9. Asthma
  10. Cough

60+:

  1. Cardiac failure congestive
  2. Fall
  3. Headache (pain in head)
  4. Herpes zoster
  5. Injury
  6. Neuropathy peripheral (surface nerve damage)
  7. Pancytopenia (medical condition in which there is a reduction in the number of red and white blood cells, as well as platelets)
  8. Productive cough
  9. Amnesia (deficit in memory caused by brain damage, disease, or psychological trauma)
  10. Aortic stenosis (obstruction to the outflow of blood from the left ventricle into the aorta)

What are the existing conditions these people have? *

  1. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 18 people, 36.00%
  2. Diabetes: 11 people, 22.00%
  3. High Blood Cholesterol: 10 people, 20.00%
  4. Pain: 9 people, 18.00%
  5. Nausea (feeling of having an urge to vomit): 7 people, 14.00%
  6. Depression: 6 people, 12.00%
  7. Urinary Tract Infection: 5 people, 10.00%
  8. Hyperlipidaemia (presence of excess lipids in the blood): 5 people, 10.00%
  9. Cough: 5 people, 10.00%
  10. Kidney Infection (Pyelonephritis): 5 people, 10.00%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and Omnicef?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Carvedilol and Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Omnicef:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Carvedilol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Omnicef and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on carvedilol and cefdinir (the active ingredients of Carvedilol and Omnicef, respectively), and Carvedilol and Omnicef (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: